MX346678B - Sales de arginina utiles inmunologicamente. - Google Patents

Sales de arginina utiles inmunologicamente.

Info

Publication number
MX346678B
MX346678B MX2014010423A MX2014010423A MX346678B MX 346678 B MX346678 B MX 346678B MX 2014010423 A MX2014010423 A MX 2014010423A MX 2014010423 A MX2014010423 A MX 2014010423A MX 346678 B MX346678 B MX 346678B
Authority
MX
Mexico
Prior art keywords
arginine salts
immunologically useful
immunologically
useful
arginine
Prior art date
Application number
MX2014010423A
Other languages
English (en)
Spanish (es)
Other versions
MX2014010423A (es
Inventor
Jain Siddhartha
Kay Dodd Stephanie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014010423A publication Critical patent/MX2014010423A/es
Publication of MX346678B publication Critical patent/MX346678B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2014010423A 2012-03-07 2013-03-07 Sales de arginina utiles inmunologicamente. MX346678B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (2)

Publication Number Publication Date
MX2014010423A MX2014010423A (es) 2014-09-22
MX346678B true MX346678B (es) 2017-03-29

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010423A MX346678B (es) 2012-03-07 2013-03-07 Sales de arginina utiles inmunologicamente.

Country Status (18)

Country Link
US (1) US9320748B2 (cg-RX-API-DMAC7.html)
EP (1) EP2822947B1 (cg-RX-API-DMAC7.html)
JP (1) JP6325986B2 (cg-RX-API-DMAC7.html)
CN (1) CN104203946B (cg-RX-API-DMAC7.html)
AU (1) AU2013229466A1 (cg-RX-API-DMAC7.html)
CA (1) CA2865759C (cg-RX-API-DMAC7.html)
CY (1) CY1118091T1 (cg-RX-API-DMAC7.html)
DK (1) DK2822947T3 (cg-RX-API-DMAC7.html)
ES (1) ES2597755T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161354T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030175T2 (cg-RX-API-DMAC7.html)
LT (1) LT2822947T (cg-RX-API-DMAC7.html)
MX (1) MX346678B (cg-RX-API-DMAC7.html)
PL (1) PL2822947T3 (cg-RX-API-DMAC7.html)
PT (1) PT2822947T (cg-RX-API-DMAC7.html)
RU (1) RU2014140336A (cg-RX-API-DMAC7.html)
SI (1) SI2822947T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013131985A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
BR112013022397A2 (pt) 2011-03-02 2017-09-26 Derek O’Hagan vacinas combinadas com doses menores de antígeno e/ou adjuvante
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
JP6894237B2 (ja) 2014-03-26 2021-06-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 変異体ブドウ球菌抗原
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
US20230110516A1 (en) * 2020-03-01 2023-04-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
DE69334197T2 (de) 1992-03-02 2008-12-11 Novartis Vaccines And Diagnostics S.R.L. Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU695769B2 (en) 1994-07-01 1998-08-20 Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Helicobacter proteins and vaccines
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
WO2003049762A2 (en) 2001-12-12 2003-06-19 Chiron Srl. Immunisation against chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP2353608B1 (en) 2002-10-11 2019-12-18 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
CA2557353A1 (en) 2004-03-02 2005-09-15 Chiron Corporation Immunogenic compositions for chlamydia pneunomiae
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
CA2608278A1 (en) 2005-05-12 2006-12-28 Guido Grandi Immunogenic compositions for chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
ES2565377T3 (es) 2009-04-14 2016-04-04 Glaxosmithkline Biologicals Sa Composiciones para inmunización contra Staphylococcus aureus
CN102481354A (zh) 2009-06-01 2012-05-30 诺华有限公司 肺炎球菌RrgB分化枝的组合物
AU2010258677B2 (en) * 2009-06-10 2016-10-06 Glaxosmithkline Biologicals S.A. Benzonaphthyridine-containing vaccines
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
EA026401B1 (ru) 2009-09-02 2017-04-28 Новартис Аг Иммуногенные композиции, содержащие модуляторы активности tlr
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
WO2013030378A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens

Also Published As

Publication number Publication date
MX2014010423A (es) 2014-09-22
US9320748B2 (en) 2016-04-26
CN104203946A (zh) 2014-12-10
RU2014140336A (ru) 2016-04-27
EP2822947B1 (en) 2016-08-03
AU2013229466A1 (en) 2014-09-04
DK2822947T3 (en) 2016-09-19
CA2865759C (en) 2020-07-21
SI2822947T1 (sl) 2016-10-28
ES2597755T3 (es) 2017-01-20
US20150125475A1 (en) 2015-05-07
LT2822947T (lt) 2016-10-10
CA2865759A1 (en) 2013-09-12
PT2822947T (pt) 2016-09-26
HRP20161354T1 (hr) 2016-12-02
JP2015511957A (ja) 2015-04-23
PL2822947T3 (pl) 2017-01-31
CY1118091T1 (el) 2017-06-28
WO2013131985A1 (en) 2013-09-12
CN104203946B (zh) 2017-03-22
JP6325986B2 (ja) 2018-05-16
HUE030175T2 (en) 2017-04-28
EP2822947A1 (en) 2015-01-14

Similar Documents

Publication Publication Date Title
MX346678B (es) Sales de arginina utiles inmunologicamente.
AR117799A2 (es) Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración
PH12012502138B1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
MX2015014298A (es) Compuestos de dihidropirido pirimidina como inhibidores de autotaxina.
IL236965B (en) Derivatives of 5-aminolevulinic acid and uses thereof
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
AU342936S (en) Insole
BR112014000256A2 (pt) formulação de microemulsões transparentes e nutritivas
AU345534S (en) Indoor growing unit
AU343717S (en) Sticking plaster used for medical purposes
IN2015DN00085A (cg-RX-API-DMAC7.html)
ZA201306239B (en) Storage-stable formulation of paracetamol in aqueous solution
IN2014DN10658A (cg-RX-API-DMAC7.html)
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
EP2986112A4 (en) PREPARATION AND USE OF FULVINIC ACID DERIVATIVES
EP3004069A4 (en) HUMINIC ACID DERIVATIVES AND METHOD FOR THE PREPARATION AND USE
MX2013014420A (es) Composiciones en gel.
IN2014MN01871A (cg-RX-API-DMAC7.html)
IN2013CH04330A (cg-RX-API-DMAC7.html)
FR2989685B1 (fr) Acide lichesterinique et ses derives comme inhibiteurs de pigmentation

Legal Events

Date Code Title Description
FG Grant or registration